Overactive Bladder Treatment (OAB) Market by Drug type ( Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron), Botox, Neuromodulation, Disease Type (Idopathic OAB and Neurogenic OAB) and Region - Global Forecasts to 2027

Abstract
The global overactive bladder treatment market is projected to reach USD 4.2 billion by 2027 from USD 3.5 billion in 2022, at a CAGR of 3.6% during the forecast period. Rising prevalence of overactive bladder across the globe coupled with rising awareness about treatment options available is driving the growth of the market. Additionally, use of neuromodulation techniques for the treatment of OAB is further expected to have significant positive impact.

“Mirabergon segment dominates the overactive bladder (OAB) treatment market in 2021.”

Based on type, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, neuromodulation, and other treatments. Mirabegron held a dominant share of the market in 2021, owing to the lesser side-effects associated with this drug compared to other drug classes available in the market. Furthermore, neuromodulation segment is expected to grow at faster pace owing to launch of new SNM & PTNS for OAB in market.

“The idiopathic overactive bladder segment will witness the highest growth in overactive bladder treatment market during the forecast period.”

Based on disease type, the overactive bladder treatment market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. The idiopathic overactive bladder segment accounted for a larger market share due to the higher prevalence of idiopathic overactive bladder disorders and increased use of drugs for the treatment.

“North America held dominant share in 2021.”

Geographically, the overactive bladder (OAB) treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the major share in the OAB treatment market. North America holds majority of the key market players leading to maturity of OAB treatment market in this region. Furthermore, favorable reimbursement policies in US is one of the leading factor projecting market growth in North America.

The primary interviews conducted for this report can be categorized as follows:
•By Company Type – Supply Side: 80.0%, Demand Side: 20.0%
•By Designation – Managers: 45.0%, CXOs & Directors:30.0%, Excecutives:25.0%
•By Region - North America: 55%, Europe: 20%, Asia Pacific: 10%, Latin America: 10%, and the Middle East and Africa: 5%

List of Companies Profiled in the Report
oAstellas Pharma Inc. (Japan)
oTeva Pharmaceutical Industries Ltd. (Israel)
oPfizer Inc. (US)
oAbbvie Inc. (US)
oViatris Inc. (US)
oHisamitsu Pharmaceutical Co., Inc. (Japan)
oJohnson & Johnson Services, Inc. (US)
oEndo Pharmaceuticals Inc. (Ireland)
oLupin (India)
oAmneal Pharmaceuticals Llc (US)
oSun Pharmaceutical Industries Ltd. (India)
oGlenmark (India)
oMacleods Pharmaceuticals Ltd (India)
oMedtronic (Ireland)
oAjanta Pharma (India)
oGranules India Limited (India)
oUrovant Sciences (US)
oApotex Inc. (Canada)
oLaborie (US)
oIntas Pharmaceuticals Ltd. (India)
oBayer Ag (Germany)
oMedytox (South Korea)
oAltherx Pharmaceuticals (US)
oTaiho Pharmaceutical Co., Ltd. (Japan)
oHugel, Inc. (South Korea)

Research Coverage:
This report provides a detailed picture of the global overactive bladder treatment market. It aims at estimating the size and future growth potential of the market across different segments, such as type, disease type and region. The report also analyzes factors (such as drivers, restraints, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total cell analysis market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
•Market Penetration: Comprehensive information on cell analysis offered by the top 25 players in the cell analysis market. The report analyses the overactive bladder treatment market by type, disease type and region.
•Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various cell analysis across key geographic regions.
•Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the overactive bladder (OAB) treatment market.
•Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the overactive bladder treatment market.

Content
Table of Contents

1INTRODUCTION28
1.1OBJECTIVES OF THE STUDY28
1.2MARKET DEFINITION28
1.2.1INCLUSIONS & EXCLUSIONS29
1.3MARKET SCOPE29
1.3.1MARKETS COVERED29
1.3.2YEARS CONSIDERED30
1.4CURRENCY30
1.5LIMITATIONS30
1.6STAKEHOLDERS31
1.7SUMMARY OF CHANGES31
2RESEARCH METHODOLOGY33
2.1RESEARCH APPROACH33
FIGURE 1RESEARCH DESIGN33
2.1.1PRIMARY RESEARCH34
FIGURE 2OVERACTIVE BLADDER TREATMENT MARKET: PRIMARY RESPONDENTS34
2.1.2TOP-DOWN AND BOTTOM-UP APPROACHES35
FIGURE 3MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH35
FIGURE 4MARKET SIZE ESTIMATION: REVENUE-BASED ESTIMATION36
2.2DATA TRIANGULATION APPROACH37
FIGURE 5DATA TRIANGULATION METHODOLOGY37
2.2.1SECONDARY RESEARCH37
2.2.2COVID-19-SPECIFIC ASSUMPTIONS38
2.3RESEARCH LIMITATIONS39
2.4RISK ASSESSMENT39
2.5GROWTH RATE ASSUMPTIONS/GROWTH FORECAST39
2.5.1SUPPLY SIDE39
2.5.2DEMAND SIDE40
2.5.2.1Insights from primary experts40
3EXECUTIVE SUMMARY41
FIGURE 6OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION)41
FIGURE 7OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE
2022 VS. 2027 (USD MILLION)42
FIGURE 8GEOGRAPHICAL SNAPSHOT OF THE OVERACTIVE
BLADDER TREATMENT MARKET43
 
4PREMIUM INSIGHTS44
4.1OVERACTIVE BLADDER TREATMENT MARKET OVERVIEW44
FIGURE 9RISING PREVALENCE OF OVERACTIVE BLADDER SYNDROME AND FAVORABLE REIMBURSEMENT POLICIES ARE KEY FACTORS DRIVING MARKET GROWTH44
4.2ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY TYPE AND COUNTRY (2021)45
FIGURE 10MIRABEGRON ACCOUNTED FOR THE LARGEST SHARE OF
THE ASIA PACIFIC MARKET IN 202145
4.3OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY DISEASE TYPE, 2022 VS. 202746
FIGURE 11IDIOPATHIC OVERACTIVE BLADDER SYNDROME SEGMENT WILL
CONTINUE TO DOMINATE THE MARKET IN 202746
4.4OVERACTIVE BLADDER TREATMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES47
FIGURE 12US TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD47
5MARKET OVERVIEW48
5.1INTRODUCTION48
5.2MARKET DYNAMICS49
FIGURE 13OVERACTIVE BLADDER TREATMENT MARKET: DRIVERS,
RESTRAINTS, OPPORTUNITIES, AND CHALLENGES49
TABLE 1OVERACTIVE BLADDER TREATMENT MARKET: IMPACT ANALYSIS49
5.2.1MARKET DRIVERS50
5.2.1.1Rising prevalence of overactive bladder syndrome50
5.2.1.2Rapidly aging population and subsequent rise in incidence of diseases characterized by OAB50
FIGURE 14PROJECTED GROWTH IN THE ELDERLY POPULATION ABOVE 60,
2015 VS. 2030 VS. 205051
5.2.1.3Development and use of innovative intravesical therapies52
5.2.1.4Growing R&D investments and the launch of novel therapies
in the coming years52
5.2.2MARKET RESTRAINTS53
5.2.2.1Frequent product recalls53
5.2.2.2Increased side effects of anticholinergic drugs53
5.2.3MARKET OPPORTUNITIES53
5.2.3.1Novel treatments, robust pipelines, and patent cliff of certain drugs53
5.2.4MARKET CHALLENGES54
5.2.4.1Social stigma and lack of awareness about OAB54
5.3IMPACT OF UNCERTAINTIES ON THE OVERACTIVE BLADDER TREATMENT MARKET55
FIGURE 15SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE OVERACTIVE BLADDER TREATMENT MARKET55
5.4IMPACT OF COVID-19 ON THE OVERACTIVE BLADDER TREATMENT MARKET56
5.5TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES56
FIGURE 16REVENUE SHIFT AND NEW POCKETS FOR THE OVERACTIVE BLADDER TREATMENT MARKET56
 
5.6VALUE CHAIN ANALYSIS57
FIGURE 17VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE57
5.7SUPPLY CHAIN ANALYSIS58
FIGURE 18DIRECT DISTRIBUTION—THE PREFERRED STRATEGY OF
PROMINENT COMPANIES58
5.8ECOSYSTEM ANALYSIS59
FIGURE 19ECOSYSTEM ANALYSIS OF THE PHARMACEUTICAL INDUSTRY59
FIGURE 20ECOSYSTEM ANALYSIS OF THE UROLOGY DEVICES INDUSTRY60
5.9REGULATORY SCENARIO60
5.9.1PHARMACEUTICAL INDUSTRY60
5.9.1.1Regulatory requirements61
5.9.1.1.1EU regulations61
5.9.1.1.2US regulations61
5.9.2MEDICAL DEVICE INDUSTRY61
5.9.2.1Regulatory requirements62
5.9.2.1.1EU regulations62
5.9.2.1.2US regulations62
TABLE 2LIST OF REGULATORY AUTHORITIES63
5.10TECHNOLOGY ANALYSIS64
5.11KEY CONFERENCES AND EVENTS IN 2022–202364
TABLE 3OVERACTIVE BLADDER TREATMENT MARKET: LIST OF
CONFERENCES AND EVENTS64
5.12PATENT ANALYSIS65
FIGURE 21LIST OF MAJOR PATENTS IN THE OVERACTIVE BLADDER TREATMENT MARKET65
TABLE 4OVERVIEW OF PATENTS IN THE OVERACTIVE BLADDER TREATMENT MARKET66
5.13PORTER’S FIVE FORCES ANALYSIS67
TABLE 5OVERACTIVE BLADDER TREATMENT MARKET:
PORTER’S FIVE FORCES ANALYSIS67
5.13.1THREAT FROM NEW ENTRANTS67
5.13.2THREAT FROM SUBSTITUTES67
5.13.3BARGAINING POWER OF BUYERS67
5.13.4BARGAINING POWER OF SUPPLIERS68
5.13.5DEGREE OF COMPETITION68
5.14PRICING ANALYSIS68
TABLE 6COST OF DRUGS USED IN OVERACTIVE BLADDER TREATMENT
IN VARIOUS REGIONS (GENERICS)68
TABLE 7COST OF BOTOX AND NEUROMODULATION USED IN OVERACTIVE
BLADDER TREATMENT IN VARIOUS REGIONS68
TABLE 8COST OF BRANDED DRUGS USED IN OVERACTIVE BLADDER
TREATMENT IN VARIOUS REGIONS69
5.15KEY STAKEHOLDERS AND BUYING CRITERIA69
FIGURE 22KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND THEIR INFLUENCE ON THE BUYING PROCESS69
FIGURE 23KEY BUYING CRITERIA FOR OVERACTIVE BLADDER TREATMENT PRODUCTS AMONG END USERS70
5.16PIPELINE ANALYSIS70
FIGURE 24PIPELINE ANALYSIS: PHASES OF DRUGS IN CLINICAL TRIALS70
6OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE71
6.1INTRODUCTION72
TABLE 9OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION)72
TABLE 10OVERACTIVE BLADDER TREATMENT MARKET, BY REGION,
2020–2027 (USD MILLION)72
6.2MIRABEGRON73
6.2.1FEWER SIDE EFFECTS COMPARED WITH ANTICHOLINERGICS ARE LIKELY TO PROPEL THE GROWTH OF THIS MARKET SEGMENT73
TABLE 11OVERACTIVE BLADDER TREATMENT MARKET FOR MIRABEGRON, BY REGION, 2020–2027 (USD MILLION)73
6.3ANTICHOLINERGICS74
TABLE 12OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS,
BY REGION, 2020–2027 (USD MILLION)74
TABLE 13OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS,
BY TYPE, 2020–2027 (USD MILLION)75
6.3.1SOLIFENACIN75
6.3.1.1Solifenacin is more effective than other anticholinergics in reducing the frequency of incontinence—a key factor driving market growth75
TABLE 14OVERACTIVE BLADDER TREATMENT MARKET FOR SOLIFENACIN,
BY REGION, 2020–2027 (USD MILLION)76
6.3.2OXYBUTYNIN76
6.3.2.1Oxybutynin is the most widely prescribed anticholinergic drug in the OAB market76
TABLE 15OVERACTIVE BLADDER TREATMENT MARKET FOR OXYBUTYNIN,
BY REGION, 2020–2027 (USD MILLION)77
6.3.3FESOTERODINE77
6.3.3.1Fesoterodine exhibits antimuscarinic effects on the muscarinic acetylcholine receptors in the detrusor muscle, leading to a decrease in bladder contractions77
TABLE 16OVERACTIVE BLADDER TREATMENT MARKET FOR FESOTERODINE,
BY REGION, 2020–2027 (USD MILLION)78
6.3.4DARIFENACIN78
6.3.4.1Cost of darifenacin is higher than other anticholinergics, which is likely to restrain market growth to a certain extent78
TABLE 17OVERACTIVE BLADDER TREATMENT MARKET FOR DARIFENACIN,
BY REGION, 2020–2027 (USD MILLION)79
6.3.5TOLTERODINE79
6.3.5.1Tolterodine is the third-most-prescribed drug for OAB as it has fewer side effects and offers long-term clinical efficacy79
TABLE 18OVERACTIVE BLADDER TREATMENT MARKET FOR TOLTERODINE, BY REGION, 2020–2027 (USD MILLION)80
 
6.3.6TROSPIUM80
6.3.6.1Trospium is associated with a lower incidence of dry mouth, as a result of which its discontinuation rate is relatively low80
TABLE 19OVERACTIVE BLADDER TREATMENT MARKET FOR TROSPIUM,
BY REGION, 2020–2027 (USD MILLION)81
6.3.7OTHER ANTICHOLINERGICS81
TABLE 20OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER ANTICHOLINERGICS, BY REGION, 2020–2027 (USD MILLION)81
6.4BOTOX82
6.4.1HIGHER EFFICACY OF BOTOX THAN ANTICHOLINERGICS MAKES IT A POPULAR TREATMENT ALTERNATIVE82
TABLE 21OVERACTIVE BLADDER TREATMENT MARKET FOR BOTOX, BY REGION,
2020–2027 (USD MILLION)82
6.5NEUROMODULATION83
6.5.1INCREASING ADOPTION OF NEUROMODULATION FOR OVERACTIVE BLADDER TREATMENT TO DRIVE GROWTH IN THIS MARKET SEGMENT83
TABLE 22OVERACTIVE BLADDER TREATMENT MARKET FOR NEUROMODULATION,
BY REGION, 2020–2027 (USD MILLION)83
6.6OTHER TREATMENTS84
TABLE 23OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER TREATMENTS,
BY REGION, 2020–2027 (USD MILLION)84
7OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE85
7.1INTRODUCTION86
TABLE 24OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)86
7.2IDIOPATHIC OVERACTIVE BLADDER SYNDROME87
7.2.1AVAILABILITY OF REIMBURSEMENTS FOR DRUGS USED TO TREAT IDIOPATHIC OAB TO FUEL GROWTH IN THIS MARKET87
TABLE 25IDIOPATHIC OVERACTIVE BLADDER TREATMENT MARKET, BY REGION,
2020–2027 (USD MILLION)87
7.3NEUROGENIC OVERACTIVE BLADDER SYNDROME88
TABLE 26NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020–2027 (USD MILLION)88
TABLE 27NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION)89
7.3.1PARKINSON'S DISEASE89
7.3.1.1Increased use of anticholinergics and beta-adrenergic agonists for the treatment of Parkinson’s disease to drive market growth89
TABLE 28NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR PARKINSON’S DISEASE, BY REGION, 2020–2027 (USD MILLION)90
7.3.2STROKES90
7.3.2.1Rising prevalence of strokes to increase the incidence of OAB and fuel the demand for OAB treatment90
TABLE 29NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR STROKES,
BY REGION, 2020–2027 (USD MILLION)91
7.3.3MULTIPLE SCLEROSIS91
7.3.3.1Favorable reimbursement policies to support the growth of the
OAB treatment market for MS91
TABLE 30NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2020–2027 (USD MILLION)92
7.3.4SPINAL CORD INJURIES92
7.3.4.1High prevalence of bladder overactivity in SCI contributes to the growth of the neurogenic bladder overactivity treatment market92
TABLE 31NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR SPINAL CORD INJURIES, BY REGION, 2020–2027 (USD MILLION)93
7.3.5OTHER DISORDERS93
TABLE 32NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER DISORDERS, BY REGION, 2020–2027 (USD MILLION)94
8OVERACTIVE BLADDER TREATMENT MARKET, BY REGION95
8.1INTRODUCTION96
TABLE 33OVERACTIVE BLADDER TREATMENT MARKET, BY REGION,
2020–2027 (USD MILLION)96
8.2NORTH AMERICA96
FIGURE 25NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT97
TABLE 34NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)97
TABLE 35NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)98
TABLE 36NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)98
TABLE 37NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)99
TABLE 38NORTH AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)99
8.2.1US99
8.2.1.1Favorable reimbursement policies make the US the largest market for bladder overactivity treatment99
TABLE 39US: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION)100
TABLE 40US: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS,
BY TYPE, 2020–2027 (USD MILLION)101
TABLE 41US: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)101
TABLE 42US: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)102
8.2.2CANADA102
8.2.2.1Increased use of and demand for BOTOX to treat overactive bladder to drive market growth in Canada102
TABLE 43CANADA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION)103
TABLE 44CANADA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)103
TABLE 45CANADA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)104
TABLE 46CANADA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)104
8.3EUROPE104
TABLE 47EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION)105
TABLE 48EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION)105
TABLE 49EUROPE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)106
TABLE 50EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)106
TABLE 51EUROPE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)107
8.3.1GERMANY107
8.3.1.1Aging population and a high prevalence of OAB, especially in women, are expected to increase target patient groups in Germany107
TABLE 52GERMANY: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION)108
TABLE 53GERMANY: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)108
TABLE 54GERMANY: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)109
TABLE 55GERMANY: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)109
8.3.2UK109
8.3.2.1Initiatives and awareness campaigns in the UK to drive growth
in the OAB market109
TABLE 56ANNUAL COST OF OVERACTIVE BLADDER TREATMENT IN THE UK110
TABLE 57UK: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION)111
TABLE 58UK: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS,
BY TYPE, 2020–2027 (USD MILLION)111
TABLE 59UK: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)112
TABLE 60UK: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)112
8.3.3FRANCE112
8.3.3.1Low reimbursement rate in France compared to other countries may limit market growth to a certain extent112
TABLE 61REIMBURSEMENT RATES FOR OVERACTIVE BLADDER TREATMENT IN FRANCE113
TABLE 62FRANCE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION)113
TABLE 63FRANCE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)114
TABLE 64FRANCE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)114
TABLE 65FRANCE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)115
8.3.4ITALY115
8.3.4.1Italian pharmaceutical industry is expected to offer lucrative growth opportunities to OAB drug manufacturers115
TABLE 66ITALY: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION)116
TABLE 67ITALY: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)116
TABLE 68ITALY: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)117
TABLE 69ITALY: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)117
8.3.5SPAIN117
8.3.5.1Changing demographics and high OAB prevalence in Spain offer significant growth opportunities for the bladder overactivity treatment market117
TABLE 70SPAIN: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION)118
TABLE 71SPAIN: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)119
TABLE 72SPAIN: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)119
TABLE 73SPAIN: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)120
8.3.6REST OF EUROPE120
TABLE 74REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)120
TABLE 75REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)121
TABLE 76REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)121
TABLE 77REST OF EUROPE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)122
8.4ASIA PACIFIC122
FIGURE 26ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT123
TABLE 78ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)124
TABLE 79ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION)124
TABLE 80ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)125
TABLE 81ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)125
TABLE 82ASIA PACIFIC: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)126
8.4.1JAPAN126
8.4.1.1Advancements in treatment options to fuel growth
in the market in Japan126
TABLE 83JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION)127
TABLE 84JAPAN: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)127
TABLE 85JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)128
TABLE 86JAPAN: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)128
8.4.2CHINA128
8.4.2.1Growing adoption of BOTOX for OAB treatment makes China a lucrative market128
TABLE 87CHINA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION)129
TABLE 88CHINA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)130
TABLE 89CHINA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)130
TABLE 90CHINA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)131
8.4.3INDIA131
8.4.3.1India is the world’s largest producer of generic drugs— a key factor driving market growth131
TABLE 91INDIA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION)132
TABLE 92INDIA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)132
TABLE 93INDIA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)133
TABLE 94INDIA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)133
8.4.4AUSTRALIA133
8.4.4.1Growing aging population is likely to increase the number of patients suffering from OAB in Australia—a major factor supporting the growth of this market133
TABLE 95AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION)134
TABLE 96AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)134
TABLE 97AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)135
TABLE 98AUSTRALIA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)135
8.4.5REST OF ASIA PACIFIC135
TABLE 99REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)136
TABLE 100REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)136
TABLE 101REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET,
BY DISEASE TYPE, 2020–2027 (USD MILLION)137
TABLE 102REST OF ASIA PACIFIC: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)137
8.5LATIN AMERICA138
TABLE 103LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)138
TABLE 104LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)138
TABLE 105LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)139
TABLE 106LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET,
BY DISEASE TYPE, 2020–2027 (USD MILLION)139
TABLE 107LATIN AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)140
8.5.1BRAZIL140
8.5.1.1Increased use of overactive bladder drugs in the country to
drive growth in the market140
FIGURE 27DISTRIBUTION OF POPULATION IN BRAZIL (ABOVE-60 AGE GROUP),
2004–2050140
TABLE 108BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION)141
TABLE 109BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)141
TABLE 110BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)142
TABLE 111BRAZIL: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)142
8.5.2MEXICO142
8.5.2.1Rising prevalence of OAB to drive growth in the market in Mexico142
TABLE 112MEXICO: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION)143
TABLE 113MEXICO: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)143
TABLE 114MEXICO: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)144
TABLE 115MEXICO: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)144
8.5.3REST OF LATIN AMERICA145
TABLE 116REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)145
TABLE 117REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)145
TABLE 118REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET,
BY DISEASE TYPE, 2020–2027 (USD MILLION)146
TABLE 119REST OF LATIN AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)146
 
8.6MIDDLE EAST & AFRICA146
8.6.1RISING AWARENESS OF OAB IS LIKELY TO DRIVE THE GROWTH OF THE MARKET IN THE MIDDLE EAST & AFRICA146
TABLE 120MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION)147
TABLE 121MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)147
TABLE 122MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET,
BY DISEASE TYPE, 2020–2027 (USD MILLION)148
TABLE 123MIDDLE EAST & AFRICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)148
9COMPETITIVE LANDSCAPE149
9.1INTRODUCTION149
9.2RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS149
FIGURE 28OVERACTIVE BLADDER TREATMENT MARKET: STRATEGIES ADOPTED
BY KEY PLAYERS149
9.3MARKET SHARE ANALYSIS150
FIGURE 29OVERACTIVE BLADDER TREATMENT MARKET: MARKET
SHARE ANALYSIS OF KEY PLAYERS (2021)150
TABLE 124OVERACTIVE BLADDER TREATMENT MARKET: DEGREE OF COMPETITION150
9.4REVENUE ANALYSIS152
FIGURE 30REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021)152
9.5COMPANY EVALUATION QUADRANT152
9.5.1STARS153
9.5.2EMERGING LEADERS153
9.5.3PERVASIVE PLAYERS153
9.5.4PARTICIPANTS153
FIGURE 31OVERACTIVE BLADDER TREATMENT MARKET:
COMPANY EVALUATION MATRIX, 2021154
9.6COMPETITIVE BENCHMARKING OF TOP 20 PLAYERS155
9.6.1COMPANY FOOTPRINT (20 COMPANIES)155
TABLE 125COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS IN
THE OVERACTIVE BLADDER TREATMENT MARKET155
9.6.2COMPANY PRODUCT FOOTPRINT (20 COMPANIES)156
TABLE 126PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN
THE OVERACTIVE BLADDER TREATMENT MARKET156
9.6.3COMPANY REGIONAL FOOTPRINT (20 COMPANIES)157
TABLE 127REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
IN THE OVERACTIVE BLADDER TREATMENT MARKET157
9.7COMPANY EVALUATION QUADRANT: START-UPS/SMES158
9.7.1PROGRESSIVE COMPANIES158
9.7.2STARTING BLOCKS158
9.7.3RESPONSIVE COMPANIES158
9.7.4DYNAMIC COMPANIES158
FIGURE 32OVERACTIVE BLADDER TREATMENT MARKET:
COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021159
9.7.5COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS160
TABLE 128OVERACTIVE BLADDER TREATMENT MARKET: DETAILED LIST OF
KEY START-UPS/SMES160
TABLE 129OVERACTIVE BLADDER TREATMENT MARKET:
COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)161
9.8COMPETITIVE SCENARIO AND TRENDS162
9.8.1PRODUCT LAUNCHES & APPROVALS162
TABLE 130PRODUCT LAUNCHES & APPROVALS, JANUARY 2019–MAY 2022162
9.8.2DEALS162
TABLE 131DEALS, JANUARY 2019–MAY 2022162
10COMPANY PROFILES163
10.1KEY PLAYERS163
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1ASTELLAS PHARMA INC.163
TABLE 132ASTELLAS PHARMA INC.: BUSINESS OVERVIEW163
FIGURE 33ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2021)164
10.1.2TEVA PHARMACEUTICAL INDUSTRIES LTD.166
TABLE 133TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW166
FIGURE 34TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)166
10.1.3PFIZER INC.168
TABLE 134PFIZER INC.: BUSINESS OVERVIEW168
FIGURE 35PFIZER INC.: COMPANY SNAPSHOT (2021)169
10.1.4ABBVIE INC.171
TABLE 135ABBVIE INC.: BUSINESS OVERVIEW171
FIGURE 36ABBVIE INC.: COMPANY SNAPSHOT (2021)172
10.1.5VIATRIS INC.173
TABLE 136VIATRIS INC.: BUSINESS OVERVIEW173
FIGURE 37VIATRIS INC.: COMPANY SNAPSHOT (2021)174
10.1.6HISAMITSU PHARMACEUTICAL CO., INC.175
TABLE 137HISAMITSU PHARMACEUTICAL CO., INC.: BUSINESS OVERVIEW175
FIGURE 38HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2020)175
10.1.7JOHNSON & JOHNSON SERVICES, INC.176
TABLE 138JOHNSON & JOHNSON SERVICES, INC.: BUSINESS OVERVIEW176
FIGURE 39JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2021)176
10.1.8ENDO PHARMACEUTICALS INC.178
TABLE 139ENDO PHARMACEUTICALS INC.: BUSINESS OVERVIEW178
FIGURE 40ENDO PHARMACEUTICALS INC.: COMPANY SNAPSHOT178
10.1.9LUPIN179
TABLE 140LUPIN: BUSINESS OVERVIEW179
FIGURE 41LUPIN: COMPANY SNAPSHOT (2021)179
10.1.10AMNEAL PHARMACEUTICALS LLC180
TABLE 141AMNEAL PHARMACEUTICALS LLC: BUSINESS OVERVIEW180
FIGURE 42AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT (2021)180
10.1.11SUN PHARMACEUTICAL INDUSTRIES LTD.182
TABLE 142SUN PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW182
FIGURE 43SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)183
10.1.12GLENMARK184
TABLE 143GLENMARK: BUSINESS OVERVIEW184
FIGURE 44GLENMARK: COMPANY SNAPSHOT (2021)184
10.1.13MACLEODS PHARMACEUTICALS LTD.186
TABLE 144MACLEODS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW186
FIGURE 45MACLEODS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2021)186
10.1.14MEDTRONIC187
TABLE 145MEDTRONIC: BUSINESS OVERVIEW187
FIGURE 46MEDTRONIC: COMPANY SNAPSHOT (2021)188
10.1.15AJANTA PHARMA190
TABLE 146AJANTA PHARMA: BUSINESS OVERVIEW190
FIGURE 47AJANTA PHARMA: COMPANY SNAPSHOT (2021)191
10.1.16GRANULES INDIA LIMITED192
TABLE 147GRANULES INDIA LIMITED: BUSINESS OVERVIEW192
FIGURE 48GRANULES INDIA LIMITED: COMPANY SNAPSHOT (2021)192
10.2OTHER PLAYERS194
10.2.1UROVANT SCIENCES194
TABLE 148UROVANT SCIENCES: BUSINESS OVERVIEW194
10.2.2APOTEX INC.195
TABLE 149APOTEX INC.: BUSINESS OVERVIEW195
10.2.3LABORIE196
TABLE 150LABORIE: BUSINESS OVERVIEW196
10.2.4INTAS PHARMACEUTICALS LTD.197
TABLE 151INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW197
10.2.5BAYER AG198
TABLE 152BAYER AG: BUSINESS OVERVIEW198
10.2.6MEDYTOX199
TABLE 153MEDYTOX: BUSINESS OVERVIEW199
10.2.7ALTHERX PHARMACEUTICALS200
TABLE 154ALTHERX PHARMACEUTICALS: BUSINESS OVERVIEW200
10.2.8TAIHO PHARMACEUTICAL CO., LTD.201
TABLE 155TAIHO PHARMACEUTICAL CO., LTD.: BUSINESS OVERVIEW201
10.2.9HUGEL, INC.202
TABLE 156HUGEL, INC.: BUSINESS OVERVIEW202
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11APPENDIX203
11.1DISCUSSION GUIDE203
11.2KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL206
11.3AVAILABLE CUSTOMIZATIONS208
11.4RELATED REPORTS208
11.5AUTHOR DETAILS209